Home » Stocks » ARQT

Arcutis Biotherapeutics, Inc. (ARQT)

Stock Price: $28.72 USD 0.09 (0.31%)
Updated Jan 19, 2021 4:00 PM EST - Market closed
Market Cap 1.25B
Revenue (ttm) n/a
Net Income (ttm) -114.20M
Shares Out 37.75M
EPS (ttm) -10.27
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 19
Last Price $28.72
Previous Close $28.63
Change ($) 0.09
Change (%) 0.31%
Day's Open 29.78
Day's Range 28.27 - 30.97
Day's Volume 240,610
52-Week Range 17.82 - 36.90

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 6 days ago

WESTLAKE VILLAGE, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a medical dermatology company developing innovative treatments for patients with immun...

GlobeNewsWire - 1 week ago

WESTLAKE VILLAGE, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treat...

GlobeNewsWire - 4 weeks ago

WESTLAKE VILLAGE, Calif., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treat...

GlobeNewsWire - 1 month ago

WESTLAKE VILLAGE, Calif., Dec. 09, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treat...

GlobeNewsWire - 1 month ago

WESTLAKE VILLAGE, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treat...

GlobeNewsWire - 1 month ago

WESTLAKE VILLAGE, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treat...

GlobeNewsWire - 1 month ago

WESTLAKE VILLAGE, Calif., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treat...

GlobeNewsWire - 1 month ago

WESTLAKE VILLAGE, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treat...

GlobeNewsWire - 2 months ago

WESTLAKE VILLAGE, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treat...

GlobeNewsWire - 2 months ago

WESTLAKE VILLAGE, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a medical dermatology company developing innovative treatments for patients with immun...

GlobeNewsWire - 2 months ago

WESTLAKE VILLAGE, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treat...

Seeking Alpha - 2 months ago

Arcutis has an upcoming phase 3 data readout catalyst in 1Q 2021. Past data has been good, with a clear competitive difference.

GlobeNewsWire - 2 months ago

WESTLAKE VILLAGE, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treat...

GlobeNewsWire - 2 months ago

WESTLAKE VILLAGE, Calif., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a medical dermatology company developing innovative treatments for patients with immun...

GlobeNewsWire - 3 months ago

WESTLAKE VILLAGE, Calif., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treat...

The Motley Fool - 3 months ago

The company announced the pricing of a public offering of common stock.

GlobeNewsWire - 3 months ago

WESTLAKE VILLAGE, Calif., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treat...

24/7 Wall Street - 3 months ago

Any time there is good news that drives a stock higher, some investors know that the companies making the news may use the strength to raise additional capital. Not all secondary offerings com...

Other stocks mentioned: CRDF, FCEL, IMXI, LAD, OMI
GlobeNewsWire - 3 months ago

WESTLAKE VILLAGE, Calif., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing tr...

GlobeNewsWire - 3 months ago

WESTLAKE VILLAGE, Calif., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing tr...

GlobeNewsWire - 4 months ago

WESTLAKE VILLAGE, Calif., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. ((Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing t...

GlobeNewsWire - 4 months ago

WESTLAKE VILLAGE, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing tr...

GlobeNewsWire - 4 months ago

WESTLAKE VILLAGE, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing tr...

GlobeNewsWire - 5 months ago

WESTLAKE VILLAGE, Calif., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing tre...

GlobeNewsWire - 5 months ago

WESTLAKE VILLAGE, Calif., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing tre...

GlobeNewsWire - 5 months ago

WESTLAKE VILLAGE, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing tre...

GlobeNewsWire - 5 months ago

WESTLAKE VILLAGE, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing tre...

GlobeNewsWire - 5 months ago

WESTLAKE VILLAGE, Calif., July 31, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing tre...

GlobeNewsWire - 5 months ago

WESTLAKE VILLAGE, Calif., July 27, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing tre...

GlobeNewsWire - 6 months ago

WESTLAKE VILLAGE, Calif., July 15, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing tre...

GlobeNewsWire - 6 months ago

WESTLAKE VILLAGE, Calif., July 13, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a medical dermatology company developing innovative treatments for patients with imm...

GlobeNewsWire - 6 months ago

WESTLAKE VILLAGE, Calif., June 22, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing tre...

GlobeNewsWire - 7 months ago

WESTLAKE VILLAGE, Calif., June 10, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing tre...

GlobeNewsWire - 7 months ago

WESTLAKE VILLAGE, Calif., June 01, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing tre...

GlobeNewsWire - 7 months ago

WESTLAKE VILLAGE, Calif., May 27, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing trea...

GlobeNewsWire - 8 months ago

WESTLAKE VILLAGE, Calif., May 12, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing trea...

GlobeNewsWire - 8 months ago

WESTLAKE VILLAGE, Calif., April 27, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing tr...

GlobeNewsWire - 8 months ago

WESTLAKE VILLAGE, Calif., April 21, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing tr...

GlobeNewsWire - 9 months ago

WESTLAKE VILLAGE, Calif., March 23, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing tr...

GlobeNewsWire - 10 months ago

WESTLAKE VILLAGE, Calif., March 16, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing tr...

GlobeNewsWire - 10 months ago

WESTLAKE VILLAGE, Calif., March 05, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing tr...

GlobeNewsWire - 10 months ago

WESTLAKE VILLAGE, Calif., March 03, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing tr...

GlobeNewsWire - 11 months ago

WESTLAKE VILLAGE, Calif., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing t...

The Motley Fool - 11 months ago

These four companies just made their debuts. Should they be on your radar?

Other stocks mentioned: BDTX, ONEM, REYN

About ARQT

Arcutis Biotherapeutics, a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical cream formulation of roflumilast that is in Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of ARQ-151 for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical small molecule inhibitor of janus kinase type 1 for hand eczema... [Read more...]

Industry
Biotechnology
IPO Date
Jan 31, 2020
CEO
Todd Franklin Watanabe
Employees
53
Stock Exchange
NASDAQ
Ticker Symbol
ARQT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for ARQT stock is "Strong Buy." The 12-month stock price forecast is 46.80, which is an increase of 62.95% from the latest price.

Price Target
$46.80
(62.95% upside)
Analyst Consensus: Strong Buy